Tau kinetics in Alzheimer's disease

被引:11
|
作者
Hier, Daniel B. [1 ,2 ]
Azizi, Sima [1 ]
Thimgan, Matthew S. [3 ]
Wunsch II, Donald C. C. [1 ,4 ]
机构
[1] Missouri Univ Sci & Technol, Dept Elect & Comp Engn, Appl Computat Intelligence Lab, Rolla, MO 65409 USA
[2] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60607 USA
[3] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA
[4] Natl Sci Fdn, ECCS Div, Alexandria, VA USA
来源
FRONTIERS IN AGING NEUROSCIENCE | 2022年 / 14卷
基金
美国国家科学基金会;
关键词
tau; Alzheimer's disease; CSF levels; plasma levels; steady state kinetics; halflife; turnover; clearance; FIBRILLARY ACIDIC PROTEIN; BRAIN INTERSTITIAL FLUID; NORMAL ORGAN WEIGHTS; II-THE-BRAIN; LONGITUDINAL STABILITY; MOUSE MODEL; PLASMA TAU; SECRETION; TURNOVER; SERUM;
D O I
10.3389/fnagi.2022.1055170
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The cytoskeletal protein tau is implicated in the pathogenesis of Alzheimer's disease which is characterized by intra-neuronal neurofibrillary tangles containing abnormally phosphorylated insoluble tau. Levels of soluble tau are elevated in the brain, the CSF, and the plasma of patients with Alzheimer's disease. To better understand the causes of these elevated levels of tau, we propose a three-compartment kinetic model (brain, CSF, and plasma). The model assumes that the synthesis of tau follows zero-order kinetics (uncorrelated with compartmental tau levels) and that the release, absorption, and clearance of tau is governed by first-order kinetics (linearly related to compartmental tau levels). Tau that is synthesized in the brain compartment can be released into the interstitial fluid, catabolized, or retained in neurofibrillary tangles. Tau released into the interstitial fluid can mix with the CSF and eventually drain to the plasma compartment. However, losses of tau in the drainage pathways may be significant. The kinetic model estimates half-life of tau in each compartment (552 h in the brain, 9.9 h in the CSF, and 10 h in the plasma). The kinetic model predicts that an increase in the neuronal tau synthesis rate or a decrease in tau catabolism rate best accounts for observed increases in tau levels in the brain, CSF, and plasma found in Alzheimer's disease. Furthermore, the model predicts that increases in brain half-life of tau in Alzheimer's disease should be attributed to decreased tau catabolism and not to increased tau synthesis. Most clearance of tau in the neuron occurs through catabolism rather than release to the CSF compartment. Additional experimental data would make ascertainment of the model parameters more precise.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] The Revitalized Tau Hypothesis on Alzheimer's Disease
    Maccioni, Ricardo B.
    Farias, Gonzalo
    Morales, Inelia
    Navarrete, Leonardo
    ARCHIVES OF MEDICAL RESEARCH, 2010, 41 (03) : 226 - 231
  • [32] Alzheimer's disease:: β-amyloid protein and tau
    Morishima-Kawashima, M
    Hara, Y
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 70 (03) : 392 - 401
  • [33] Alzheimer's disease - A new take on tau
    Marx, Jean
    SCIENCE, 2007, 316 (5830) : 1416 - 1417
  • [34] Tau is actin up in Alzheimer's disease
    Gallo, Gianluca
    NATURE CELL BIOLOGY, 2007, 9 (02) : 133 - 134
  • [35] Tau PET Imaging in Alzheimer’s Disease
    Nobuyuki Okamura
    Ryuichi Harada
    Shozo Furumoto
    Hiroyuki Arai
    Kazuhiko Yanai
    Yukitsuka Kudo
    Current Neurology and Neuroscience Reports, 2014, 14
  • [36] Nanotechnology for tau pathology in Alzheimer's disease
    Ma, Rongrong
    Mu, Qianwen
    Xi, Yue
    Liu, Gang
    Liu, Chao
    MATERIALS TODAY BIO, 2024, 27
  • [37] Tau as a drug target in Alzheimer’s disease
    Illana Gozes
    Journal of Molecular Neuroscience, 2002, 19 : 337 - 338
  • [38] Networks of tau distribution in Alzheimer's disease
    Hoenig, Merle C.
    Bischof, Gerard N.
    Seemiller, Joseph
    Hammes, Jochen
    Kukolja, Juraj
    Onur, Ozgur A.
    Jessen, Frank
    Fliessbach, Klaus
    Neumaier, Bernd
    Fink, Gereon R.
    van Eimeren, Thilo
    Drzezga, Alexander
    BRAIN, 2018, 141 : 568 - 581
  • [39] The role of tau kinases in Alzheimer's disease
    Dolan, Philip J.
    Johnson, Gail V. W.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2010, 13 (05) : 595 - 603
  • [40] Targeting Tau Protein in Alzheimer's Disease
    Gong, Cheng-Xin
    Grundke-Iqbal, Inge
    Iqbal, Khalid
    DRUGS & AGING, 2010, 27 (05) : 351 - 365